Status:
UNKNOWN
Multicenter Study on Fibrotic Valvular Heart Disease in Patients With Parkinson's Disease Treated With Dopamine Agonists
Lead Sponsor:
German Parkinson Study Group (GPS)
Collaborating Sponsors:
Competence Network on Parkinson's Disease
Conditions:
Heart Valve Diseases
Parkinson's Disease
Eligibility:
All Genders
18+ years
Brief Summary
Fibrotic valvular heart diseases are known as rare complications of long-time therapy of Parkinson's disease with ergot-derivatives including some ergot-dopamine agonists. The aim of this study is to ...
Detailed Description
Rare incidence of pleuropulmonary and retroperitoneal fibrosis are known complications during the long-time therapy of Parkinson's disease (PD) with ergot-drug derivatives including some ergot dopamin...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Diagnosis of Morbus Parkinson
- Written informed consent
Exclusion
- Patients with a history of carcinoid syndrome
- Patients with a history of post-inflammatory (rheumatic), degenerative (calcified) or ischaemic coronary heart or valvular heart disease
- Previous medication with ergot-derived drugs (eg. Methysergide, Ergotamine) except dopamine receptor agonists or anorectic drugs (eg. Fenfluramine, Dexfenfluramine)
Key Trial Info
Start Date :
March 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2013
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00196898
Start Date
March 1 2005
End Date
December 1 2013
Last Update
March 19 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum Marburg und Gießen, Neurologische Klinik
Marburg, Hesse, Germany, 35033